Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

377
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

804
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

750
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

337
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

482
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

324
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of severe acute alcoholic hepatitis in France: results of a national survey: R1.

Clinics and research in hepatology and gastroenterology·2026
Same author

COVID-19 and chronic liver disease: results from the 1219 patients French registry.

Scientific reports·2025
Same author

The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.

Infectious diseases now·2025
Same author

Salvage strategy for long-term central venous catheter-associated Staphylococcus aureus infections in children: a multi-centre retrospective study in France.

The Journal of hospital infection·2024
Same author

Aggregatibacter actinomycetemcomitans infection in children: two case reports and a review of the literature.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2024
Same author

Unveiling the cognitive network organization through cognitive performance.

Scientific reports·2024

Related Experiment Video

Updated: Apr 5, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.4K

NSAIDs in paediatrics: caution with varicella!

L Durand1,2, P Sachs3, C Lemaitre4

  • 1Pharmacie, Hôpital Robert-Debré, APHP, 48 bd Sérurier, 75019, Paris, France.

International Journal of Clinical Pharmacy
|August 23, 2015
PubMed
Summary
This summary is machine-generated.

Non-steroidal anti-inflammatory drugs (NSAIDs) may worsen bacterial infections in children with varicella (chickenpox). Caution is advised when prescribing NSAIDs to pediatric patients due to potential risks.

Keywords:
Bacterial complicationsChildrenIbuprofenInfectionNSAIDsPaediatricsVaricella

More Related Videos

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.8K

Related Experiment Videos

Last Updated: Apr 5, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.4K
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.8K

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Pharmacology

Background:

  • Varicella (chickenpox) is a common childhood illness.
  • Concerns exist regarding anti-inflammatory drugs potentially exacerbating bacterial infections in varicella patients.
  • Widespread availability of non-steroidal anti-inflammatory drugs (NSAIDs) contributes to their frequent use.

Purpose of the Study:

  • To investigate the potential role of NSAIDs in the deterioration of varicella patients.
  • To highlight the need for increased awareness and caution regarding NSAID use in pediatric varicella cases.

Main Methods:

  • Retrospective case review of three pediatric patients with varicella.
  • Analysis of clinical outcomes associated with NSAID use.

Main Results:

  • Three cases suggested a link between NSAID administration and worsened varicella outcomes.
  • NSAIDs may predispose varicella patients to severe bacterial infections.

Conclusions:

  • NSAID use in pediatric varicella patients warrants caution.
  • Enhanced patient and healthcare provider education on NSAID risks is recommended.
  • The benefit/risk balance of NSAIDs in this population requires careful consideration.